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Opinion statement
The complex syndrome of cancer cachexia (CC) that occurs in 50% to 80% cancer
patients has been identiﬁed as an independent predictor of shorter survival and
increased risk of treatment failure and toxicity, contributing to the mortality and
morbidity in this population. CC is a pathological state including a symptom cluster of
loss of muscle (skeletal and visceral) and fat, manifested in the cardinal feature of
emaciation, weakness affecting functional status, impaired immune system, and
metabolic dysfunction. The most prominent feature of CC is its non-responsiveness to
traditional treatment approaches; randomized clinical trials with appetite stimulants,
5-HT3 antagonists, nutrient supplementation, and Cox-2 inhibitors all have failed to
demonstrate success in reversing the metabolic abnormalities seen in CC. Interven-
tions based on a clear understanding of the mechanism of CC, using validated markers
relevant to the underlying metabolic abnormalities implicated in CC are much needed.
Although the etiopathogenesis of CC is poorly understood, studies have proposed that
NFkB is upregulated in CC, modulating immune and inﬂammatory responses induce the
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DOI 10.1007/s11864-010-0127-zcellular breakdown of muscle, resulting in sarcopenia. Several recent laboratory studies
have shown that n-3 fatty acid may attenuate protein degradation, potentially by
preventing NFkB accumulation in the nucleus, preventing the degradation of muscle
proteins. However, clinical trials to date have produced mixed results potentially
attributed to timing of interventions (end stage) and utilizing outcome markers such
as weight which is confounded by hydration, cytotoxic therapies, and serum cyto-
kines. We propose that selective targeting of proteasome activity with a standardized
dose of omega-3-acid ethyl esters, administered to cancer patients diagnosed with
early stage CC, in addition to a standard intervention with nutritionally adequate diet
and appetite stimulants, will alter metabolic abnormalities by downregulating NFkB,
preventing the breakdown of myoﬁbrillar proteins and resulting in increasing serum
protein markers, lean body mass, and functional status.
Introduction
The complex syndrome of cancer cachexia (CC) is a
major contributor to the mortality and morbidity of
cancer patients [1, 2•, 3•, 4, 5]. CC is a pathological
state where loss of muscle (skeletal and visceral) or
muscle and fat occurs, manifested in the cardinal
feature of emaciation, weakness affecting functional
status, impaired immune system and metabolic dys-
function [1, 2•, 3•, 4, 5]. CC occurs in 50% to 80%
cancer patients and identiﬁed as an independent
predictor of shorter survival and increases the risk of
treatment failure and toxicity in this population [1, 2•,
3•, 4, 5]. In 2006, it was estimated that over 5 million
individuals in the US suffered from cachexia because
of cancer or other conditions. CC continues to be an
important problem in clinical oncology [5].
Pathogenesis
• Although the etiopathogenesis of CC is poorly understood, multiple
biologic pathways are known to be involved, including pro-inﬂam-
matory cytokines [6–8], neuroendocrine hormones [4, 9•], down-
regulation of IGF-1 [2•] and tumor-speciﬁc factors such as proteolysis
inducing factor (PIF) [10, 11••]. Cytokines that are important in the
initiation of the acute phase response (APR) have also been hypoth-
esized in the genesis of CC [12••, 13•] or the result rather than the
cause of CC. Interleukin-6 (IL-6), may play a role in muscle wasting in
certain animal tumors, possibly through both lysosomal (cathepsin)
and non-lysosomal (proteasome) pathways [14]. TNF-alpha has been
shown to have direct catabolic effect on skeletal muscle and adipose
tissue and produces muscle atrophy through a depression of protein
synthesis and an increase in protein degradation through the ubiq-
uitin–proteasome proteolytic pathway, involving the formation of
reactive oxygen species leading to upregulation of the transcription
factor—NF-kB [15, 16]. NF-kB is a known regulator of the genes that
encode cytokines, cytokine receptors, cell-adhesion molecules, mod-
ulating immune and inﬂammatory responses by increasing produc-
tion of cytokines that induce proteolysis and breakdown of
myoﬁbrillar proteins [15–19]. The most plausible evidence thus
comes from animal studies that have demonstrated that etiopatho-
genesis of CC may be contributed by increasing proteolysis and
breakdown of myoﬁbrillar proteins and degradation by the protea-
some.
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• Common clinical manifestations of CC are muscle wasting, un-
planned weight loss, anorexia, anemia, and altered immune function
which contribute to increased fatigue, disability, and diminished
quality of life. The most prominent feature of CC is its non-respon-
siveness to traditional treatment approaches; randomized clinical tri-
als with appetite stimulants
[5, 20–25], nutrient supplementation [26, 27], 5-HT3 antagonists [28,
29], and Cox-2 inhibitors [30••] all have failed to demonstrate success
in reversing the metabolic abnormalities seen in CC. More recently,
staging guidelines have been proposed [31, 32•] for CC, indicating
that CC represents a spectrum initially observed as unplanned weight
loss (pre-cachexia) progressing through degrees of severity (four
stages) to the point where the cancer patient is depleted of both
muscle and fat, immunocompromised and will eventually die of
complications from these issues [33].
Prognosis
• Cancer cachexia has been identiﬁed as an independent predictor of
shorter survival and increases the risk of treatment failure and toxicity,
interruptionofserialtreatmentandsurvivalinthispopulation[1,2•,3•,
4, 5]. CC is much more difﬁcult to treat in the elderly and the conse-
quences of failure to correct malnutrition delays recovery and has a sig-
niﬁcant impact on functional dependence and quality of life in this
patient population [33, 34••].
Treatment
Diet and lifestyle
• Over the years, since one of the features identiﬁed in pre-cachexia is
loss of appetite and reduced food intake, CC was thus considered a
nutritional disorder seen in advanced cancer patients. Hence, it was
logical to infer that traditional approaches such as re-feeding and/or
supplementing dietary calories and proteins may resolve the issue.
However, since CC differs from starvations, to date, single modality
therapies with traditional applied nutritional regimens have failed to
demonstrate efﬁcacy in improving weight gain, including gain in lean
body mass in patients diagnosed with CC. The average caloric deﬁcit
in weight losing patients as with CC observed by us and other teams is
approximately 250–400 kcals/d. The average supplementation of
1 calorie/mL supplements have not shown to improve nutritional
status of patients on chemotherapy [35, 36]. However, recent studies
using a more calorie dense (1.5 kcals/mL) and higher protein sup-
plementation have suggested that at least weight stabilization can be
achieved [37••]; although, improvements in lean body mass has not
been observed in these studies. Our preliminary studies have also
demonstrated that high calorie and high protein supplemental (cal-
ories/proteins dense) feedings result in substitution of regular meals
and thus a reduction of caloric and protein intake in this patient
population who experience early satiety. However, since most
cachectic patients also exhibit symptoms of anorexia, and irregular
feeding patterns, it may be important to make available to them a
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intake deﬁcits and at a minimum stabilize weight loss.
• Other strategies include increasing physical activity, aerobic and anaer-
obic,asanon-pharmacologicalmeanstoimprovemuscleandbonemass
[37••,38••,39].Althoughtherationaletopotentiallyimproveleanbody
mass by increasing physical activity is sound, patients with initial symp-
tomsofCC,speciﬁcallyduringcancertreatment,reporttreatment-related
fatigue and respiratory distress in addition to physical and time limita-
tions and therefore demonstrate poor compliance. These symptoms are
accelerated in the elderly who have relatively lower steroid hormone
levelsasaresultof‘‘hormonalaging,’’loweredphysicalactivity,asaresult
of treatment-related fatigue that has been demonstrated to contribute to
lowered bone mineral density and muscle mass. These age-related con-
ditions may thus be exacerbated, resulting in falls, fractures, and general
muscle weakness [33]. However, recent studies have been more encour-
aging and have demonstrated improvements in fatigue scores with
multimodal exercise interventions [39] during chemotherapy.
• In summary, based on our work and that of others, it is clear that the
most prominent feature of cachexia was that it is a condition, unlike
cancer anorexia, non-responsive to traditional treatment approaches
alone. Although these strategies to improve appetite, intake of nutri-
ents and lean body mass (physical activity) have a scientiﬁc rationale
and merit evaluation, studies have continued to demonstrate that
reversal or control of the loss in lean body mass or skeletal and vis-
ceral proteins are difﬁcult to achieve in CC.
Pharmacological treatment
• Since anorexia is a key component of CC, current strategies are to
improve appetite by using appetite stimulants to ensure adequate
intake of nutrients. Pharmacological interventions with appetite
stimulants [5, 20–25], nutrient supplementation [26, 27], 5-HT3
antagonists [28, 29] and Cox-2 inhibitors [30••] have been utilized to
treat CC. Although anabolic steroids and Cox-2 inhibitors have been
used to treat anorexia-cachexia related to other muscle-wasting dis-
eases such as AIDS, the use of these agents in principle are contrain-
dicated in patients with cancer due to its growth promoting potential
as well as potential cytotoxic therapy-agent interactions.
Orexigenic agents
• Megesterol acetate (MA), a synthetic derivative of progestogens is
commonly used to treat cancer anorexia [20–24]. The potential
mechanism of action of MA is believed to involve stimulation of
appetite by both direct and indirect pathways affecting the metabo-
lism and production of catabolic cytokines [24]. MA has been reﬁned
to be more bioavailable as a nanocrystal oral suspension, signiﬁcantly
shortening the time to clinical response. Although appetite and weight
increases have been observed with MA, there have been neither sig-
niﬁcant increase in meaningful markers of skeletal and visceral pro-
teins nor do underlying metabolic abnormalities seen in CC.20-24.
Side effects of MA include thromboembolism at high doses, transient
adrenal insufﬁciency, edema, and central nervous system effects
(confusion, headaches, dizziness, and sleep disturbances). Progesto-
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results in decline in muscle mass, and an increase in fat mass [40].
These side effects in addition to lack of efﬁcacy to increase lean body
mass has tempered the routine use of MA for treatment of cancer
anorexia [24].
Cannabinoids
• Other common agents include Dronabinol, a cannabis derivative,
demonstrated to enhance appetite and mood in cancer patients
[25, 41]. Although the effectiveness as an appetite stimulant has been
evaluated in AIDS-related wasting disease, the pharmacokinetics of
this agent in cancer patients on active treatment has never been
examined. In addition, because of its psychoactive side effects, difﬁ-
culty in dose titration to optimize beneﬁt, minimize side effects like
dizziness, dysphoria, depression, hallucinations, alteration in psy-
chomotor function and paranoia, time to response and long-term
effects when taken orally limits the use of this agent for all cancer
patients with symptoms of cancer anorexia [41]. In addition, mood
alterations secondary to drug can be confused with dementia, espe-
cially in subjects who have never used cannabinoids in the past. In
spite of limited data on the efﬁcacy of cannabinoids to improve
underlying metabolic abnormalities seen in CC, clinicians ﬁnd it
potentially useful for adjuvant treatment in palliative care to improve
appetite in cancer patients with anorexia.
5-HT3 antagonists
• Mirtazapine (Remeron, Avanza, Zispin) is a tetracyclic antidepressant
used primarily in the treatment of depression, which may be a major
reversible contributor of lack of appetite and weight loss [28, 29].
However, as with most appetite stimulants, have not demonstrated
efﬁcacy in the cancer patient with CC. Common side effects of mirt-
azapine are dizziness, blurred vision, sedation, somnolence, malaise/
lassitude, increased appetite and subsequent weight gain, dry mouth,
and constipation.
• In summary, appetite stimulants have been shown to ameliorate or
slow anorexia and unintentional weight loss in other populations but
have not shown promise in increasing lean body mass or markers of
protein metabolism in the cachectic cancer patient. Randomized
clinical trials with appetite stimulants, supplementation with proteins,
calories, and antioxidants although produce some stabilization in
weight loss, and was not contraindicated in most cancer patients on
treatment, they have failed to demonstrate success in reversing the
metabolic abnormalities seen in CC. It is now clear that in addition to
timely nutritional approaches, interventions based on a clear under-
standing of the mechanism of CC using validated markers relevant to
the underlying metabolic abnormalities implicated in CC are much
needed.
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• There are currently no drugs approved for use to treat cancer cachexia.
Surgery
• There are no surgical options for the treatment of cancer cachexia.
Other therapies
• There are no other therapies for the treatment of cancer cachexia.
Emerging therapies
• Eicosapentaenoic acid (EPA) is an n-3 fatty acids and an essential fatty
acid that cannot be synthesized completely by mammalian tissue and
has to be consumed in the diet. These polyunsaturated fats are present
in ﬁsh oils such as cod liver, sardine, and salmon oil. There is no
established Dietary Reference Intake for n-3 fatty acids; yet, the ade-
quate intake (AI) is set at 1.6 and 1.1 g/d for men and women,
respectively. While intake in the United States occurs at much lower
than the proposed AI and no signs of deﬁciency are observed, the AI is
proposed to provide optimal health beneﬁts associated with con-
suming n-3 fatty acids [42]. Evidence from laboratory and clinical
studies has demonstrated that EPA has antitumor and anticachectic
effects. Initial studies using animal models have demonstrated that
NFkB is upregulated in CC increasing proteolysis and inducing
apoptosis in myotubes [43, 44]. Several recent laboratory studies have
shown that EPA may attenuate protein degradation, by preventing
NFkB accumulation in the nucleus [43, 44]. Administration of n-3
fatty acids and EPA capsules or supplements with EPA has been shown
to be associated to weight stabilization, gain in lean body mass, and
improvement in quality of life markers in weight losing patients with
advanced pancreatic cancer. A tumor product, PIF is produced by
cachexia-inducing murine and human tumors and initiates muscle
protein degradation directly through activation of the proteasome
pathway. The action of PIF is blocked by eicosapentaenoic acid (EPA),
which has been shown to attenuate the development of cachexia in
pancreatic cancer patients [10, 11]. Clinical trials to date have pro-
duced mixed results potentially attributed to interventions in later
stage of disease, inadequate monitoring, poor compliance, and
selection of primary outcome markers such as weight—which has
been shown to be confounded by hydration, cytotoxic therapies, and
acute disease status and serum cytokines, all of which may have
limited value in evaluating interventions in patients with CC, espe-
cially those patients on active treatment. To our knowledge, n-3 fatty
acid supplements have never been evaluated pro-actively in the early
stages of CC for the prevention of progressive protein loss in CC
populations with a relatively better prognosis or those populations
who could potentially demonstrate signiﬁcant improvement in treat-
ment outcomes, functional status, and quality of life. Based on our
preliminary observations and that of others, we hypothesize that by
selective targeting of proteasome activity by a standardized dose of n-3
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ities by downregulating NFkB, modulate PIF and inﬂammatory
response thus preventing the breakdown of myoﬁbrillar proteins
resulting in increasing serum protein markers, lean body mass and
physical function. We completed a pilot trial of 36 subjects to evaluate
the safety and effectiveness of administering 4-g Lovaza
  (omega-3-
acid ethyl esters) for a 6-week period, to cancer patients (>65% lung),
with early stages of CC (unplanned weight loss of 5% of their body
weight within the past 3 months) and observed changes in markers of
toxicity, visceral and skeletal protein status, nutritional intake, cyto-
kines, functional status and physical activity. Lovaza
 , is an FDA-
approved agent (GlaxoSmithKline IND # 45,998) that provides pre-
scription-only potency and purity, contains within each 1-g Lovaza
 
(omega-3-acid ethyl esters) gel capsule 90% omega-3-acid ethyl esters,
84% eicosapentanoic acid (EPA) and docosahexaenoic acid (DHA)
ethyl esters. Subjects were predominantly Caucasian and male with
63% diagnosed with lung cancer. 31% reported alcohol use of at least
one drink weekly and 60% of subjects reported history of smoking
with 8.6% reporting that they currently smoke. Pill count and study
agent logs indicated an average compliance of 93% of study agent and
86% compliance to nutritional intake recommendations. Anthropo-
metrics measurements such as height, weight, body mass index (BMI),
triceps skinfold and mid-arm muscle circumference measurements
remained stable with no reductions observed in these markers during
the 6-week intervention period. Slight increase in calories, carbohy-
drates and fat intake was observed and stable intake of proteins noted
over the 6 week intervention period. Most importantly, we observed
statistically signiﬁcant increases in serum albumin (P<0.0001),
moderately signiﬁcant increase in serum transferrin (P<0.07)
(Table 1), improvement in functional status and physical activity with
no toxicity related to the study drug at this dose. Although serum
levels of cytokines TNF-a (Cohen’s d 0.248) progressively increased
and IL6 decreased slightly (Cohen’s d -0.019), since patients were on
active treatment with cytotoxic agents, these were difﬁcult to interpret.
• In addition, we explored if treatment with Lovaza
  at a dose of 4 g/d
results in inhibition of proteasome activity in pre and post-treatment
serum samples from the patients in our clinical trial. Venous blood
was collected from subjects at baseline and at 6 weeks post inter-
vention into heparin-containing tubes and proteasome assay was
carried out using these samples using Proteasome ELISA Kit according
to manufacturer’s instructions (Proteasome ELISA Kit, ENZO Life
Sciences, Cat# PW0575). Complete pre and post-treatment serum
samples were available for 14 subjects for these studies Inhibition of
proteasome activity in serum samples post treatment was calculated
and plotted based on proteasome activity of pre-treatment samples.
Results demonstrated that proteasome activity was inhibited in nine
out of fourteen patients (64%) in the range of 6%–29% (Fig. 1).
Based on the evidence from these preliminary studies by our group, it
is evident that indeed standardized supplementation with n-3 fatty
acids appear to be promising agents that may attenuate protein deg-
radation by targeting the proteasomes, improve skeletal and visceral
proteins, functional status and physical activity and have enough
evidence to warrant use in well powered, randomized clinical trials to
further examine its safety, efﬁcacy, and validate the mechanisms by
which they modulate the metabolic abnormalities associated with CC.
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114 Integrative Oncology• Unlike previous studies that reported mixed results with interventions
in pancreatic cancer or late stage cancer patient populations [43–46••]
the aim of this study was to examine the initial safety, efﬁcacy and
potential mechanism by which we can prevent progression of CC
early in the diagnosis with a standardized preparation of n-3 fatty acid
supplements in a population of cancer patients with a relatively better
prognosis. We have, in addition, made an important distinction
between CC and anorexia (where appetite and weight are the primary
concern). This is an important distinction that allows us to focus on
the intermediate biomarkers of these underlying metabolic disorders,
speciﬁc to CC in addition to the symptoms of cancer anorexia. Fur-
thermore, we utilized a novel, molecular mechanism-based approach
to treating CC, which is important to move this ﬁeld of research
further.
• Clearly, there is a need to use a molecular mechanism-based approach to
identify potential agents for the treatment of CC. It may be critical to
examine the potential to intervene in pathways understood at the
molecular level to improve appetite, modify metabolic alterations that
contribute to wasting, and downregulate transcription factors or
cytokine-induced events to treat CC. Based on the evidence from
laboratory and clinical trials, it is evident that EPA is a promising
agent that may attenuate protein degradation by targeting the pro-
teasomes, and have enough evidence to warrant use in clinical trials to
examine its efﬁcacy for the treatment of CC. Although improving the
underlying metabolic abnormalities observed in CC for all patients
may not be possible, the aim must be to intervene in the early stages
of this disease to stabilize CC and prevent or delay further decline.
Both survival and quality of survival are important outcomes. Thus,
developing and reﬁning current strategies to additionally counteract
the symptom clusters of CC using multimodal interventions (nutri-
tional supplementation, appetite stimulants, and physical activity
regimen) to improve function and quality of life of cancer patients
continue to be crucial.
Figure 1. Proteasome inhibitory activity in serum samples of 14 patients with early symptoms of cancer cachexia
treated with n-3 fatty acid supplements.
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